Zeke Capital Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Zeke Capital Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$15.3K	Sell	433 -750	-63%	-$90.1K	﹤0.01%	471
2022 Q3	$267K	Hold	1,183	–	–	0.02%	346
2022 Q2	$224K	Hold	1,183	–	–	0.01%	415
2022 Q1	$295K	Hold	1,183	–	–	0.01%	376
2021 Q4	$184K	Hold	1,183	–	–	0.01%	290
2021 Q3	$237K	Hold	1,183	–	–	0.01%	256
2021 Q2	$302K	Buy	1,183 +83	+8%	+$20.7K	0.02%	226
2021 Q1	$292K	Hold	1,100	–	–	0.02%	215
2020 Q4	$406K	Hold	1,100	–	–	0.03%	150
2020 Q3	$269K	Buy	+1,100	New	+$342K	0.03%	173

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Zeke Capital Advisors's EIGR Position: Q4 2022 in Review

Zeke Capital Advisors reduced its Eiger BioPharmaceuticals, Inc. (EIGR) stake by 63% in Q4 2022, selling an estimated $90.1K and leaving 433 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #471.

Zeke Capital Advisors first reported a position in EIGR in Q3 2020 and has held it in 10 quarters since. The position peaked at $406K in Q4 2020. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

Zeke Capital Advisors held 433 shares of Eiger BioPharmaceuticals, Inc. worth $15.3K as of Q4 2022.
Zeke Capital Advisors sold 750 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $90.1K.
Eiger BioPharmaceuticals, Inc. made up ﹤0.01% of Zeke Capital Advisors's portfolio in Q4 2022, its #471 holding.
Zeke Capital Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2020 and has held it in 10 quarters since.
Zeke Capital Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $406K in Q4 2020.
81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.